Best of ASCO - 2014 Annual Meeting

 

Welcome

Kidney Cancer

Genitourinary (Nonprostate) Cancer

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A FARETES study of the efficacy and safety of testosterone in metastatic renal cell carcinoma patients with fatigue.

Ilya Tsimafeyeu

4569

A meta-analysis of randomized controlled trials for efficacy and safety of vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) adjuvant therapy in high-risk renal cell cancer (RCC).

Irbaz Bin Riaz

4567

A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma.

Ulka N. Vaishampayan

4510

A phase 2, single-arm trial of neoadjuvant axitinb plus avelumab in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx).

Axel Bex

TPS4604

A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).

Toni K. Choueiri

TPS4598

A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy (CN), metastasectomy (MS) or post-treatment biopsy (Bx).

Jianjun Gao

4520

A randomized phase II trial of pazopanib (PAZ) vs. temsirolimus (TEM) in patients (pts) with advanced clear-cell renal cell carcinoma (accRCC) with intermediate or poor-risk disease (the TemPa trial).

Amado J. Zurita

4563

A randomized, open label, multicenter phase 2 study, to evaluate the efficacy of sorafenib (So) in patients (pts) with metastatic renal cell carcinoma (mRCC) after a radical resection of the metastases: RESORT trial.

Giuseppe Procopio

4502

Active surveillance and deferred medical treatment (ASDT) in metastatic renal cell carcinoma (mRCC): Update of a single center experience and efficacy of medical treatment.

Philipp Ivanyi

4581

Alterations in key clear cell renal cell carcinoma (RCC) genes to refine patient prognosis.

Dominick Bossé

4516

Anxiety and patients: Perspectives on surveillance and adjuvant therapy in renal cell carcinoma.

Dena Battle

4571

Assessing DCE-MRI and DWI as treatment response biomarkers after SABR for primary renal cell carcinoma.

Hayley M Reynolds

e16587

Association between mutation variant allele fractions (mVAFs) and response to immunotherapy (IO) in metastatic renal cell carcinoma (mRCC).

Nazli Dizman

e16575

Association of gene expression with outcomes with everolimus as post-VEGF inhibitor therapy for renal cell carcinoma (RCC).

Eddy Shih-Hsin Yang

e16554

CABOPRE: Phase II study of cabozantinib prior to cytoreductive nephrectomy (CN) in locally advanced and/or metastatic renal cell carcinoma (mRCC).

Guillermo de Velasco

TPS4603

Cabozantinib (Cabo) in advanced non-clear cell renal cell carcinoma (nccRCC): A retrospective multicenter analysis.

Nieves Martinez Chanza

4579

Cabozantinib in metastatic renal cell carcinoma (mRCC): Real world experience from the UK.

Alfonso Gomez de Liano

e16578

CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced/metastatic renal cell carcinoma.

Nizar M. Tannir

TPS4601

Carcinomas of the renal medulla: A comprehensive genomic profiling (CGP) study.

Gennady Bratslavsky

e16586

CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial.

Arnaud Mejean

LBA3

Characterizing tumor immune microenvironment (TME) and outcomes for 409 patients (pts) treated on COMPARZ: Distinct clusters emphasize immune infiltration vs. angiogenesis.

Martin Henner Voss

4515

Clinical features and survival outcomes in a prospective spontaneous regression (SR) protocol of renal cell carcinoma (RCC) and melanoma (M) patients.

Olumide B. Gbolahan

e16585

Comparative transcriptomic profiling of renal medullary carcinoma (RMC) to determine distinct signatures and pathways associated with response to chemotherapy.

Pavlos Msaouel

4575

Comparison of adverse event costs of nivolumab combined with ipilimumab versus sunitinib for previously untreated metastatic renal cell carcinoma.

Keith Betts

e16561

Comparison of clinical outcomes with first-line pazopanib in clinical trial eligible and non-clinical trial eligible patients with renal cell carcinoma.

Eric Jonasch

4561

Comparison of prognostic models for selecting synchronous mRCC patients who would benefit from upfront cytoreductive nephrectomy followedtargeted therapy.

Wei Zheng

e16568

Comprehensive molecular and immunohistochemical analysis of advanced renal cell carcinoma patients treated with mTOR inhibitors.

Jesús GarcÃa-Donas

4559

Constitutive activation of mTOR pathways in renal cell carcinoma arising in dialyzed patients.

Ryuichi Mizuno

e16565

Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC).

Martin Henner Voss

4518

Disease-free survival in patients at highest risk of recurrent renal cell carcinoma in S-TRAC.

Alain Ravaud

4565

Early assessment by FDG PET/CT to predict short-term outcome in clear cell renal carcinoma treated with nivolumab.

Noboru Nakaigawa

e16548

Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL.

Martin Boegemann

4584

Efficacy and safety of endoscopic radiofrequency ablation for metastatic pancreatic renal cell carcinoma: A monocentric experience.

Gwenaelle Gravis

e16549

Efficacy and safety of pazopanib (PAZ) versus sunitinib (SUN) in patients (pts) with locally advanced or metastatic renal cell carcinoma (RCC): A pooled China subgroup analysis from COMPARZ studies.

Xinan Sheng

e16588

Efficacy of adjuvant vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (VEGFRi) in renal-cell carcinoma (RCC): Systematic review and meta-analysis.

Tobias Engel Ayer Botrel

e16573

Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).

Shubham Pant

4568

Functional biomarkers of homologous repair (HR) deficiency to guide novel DNA damage response targeted therapy in clear cell renal cell carcinoma (ccRCC).

Patrick Glen Pilie

4576

Gut microbiome composition to predict resistance in renal cell carcinoma (RCC) patients on nivolumab.

Lisa Derosa

4519

High dose Interleukin2 (HD IL2) in metastatic renal cell carcinoma (mRCC) after prior therapy: A single centre experience.

Shien Chow

e16558

Identification of IMDC intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma (ccRCC).

Annalisa Guida

e16577

Immune-related expression profiles and sunitinib response in metastatic clear cell renal cell carcinoma (ccRCC).

Òscar Reig

e16579

Impact of adrenergic and prostanoid inhibitors used chronobiologically on outcomes in patients with metastatic renal cell carcinoma.

Gouri Shankar Bhattacharyya

e16581

Impact of disease progression on patient reported outcomes, hospitalization, and death in patients with stage IV, renal cell carcinoma.

Junji Lin

e16550

Interim data analysis of the ADAPT trial using the modified intent to treat (mITT) population re-evaluates Rocapuldencel-T for clinical benefit over standard of care.

Robert A. Figlin

4557

KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.

Toni K. Choueiri

TPS4599

Lenvatinib + pembrolizumab in patients with renal cell carcinoma: Updated results.

Chung-Han Lee

4560

Lenvatinib in combination with everolimus in metastatic renal cell carcinoma (mRCC) resistant to antiangiogenic targeted therapy: An initial Russian experience.

Maria Volkova

e16562

Long survival (SV) for metastatic renal cell cancer (mRCC) after cytoreductive nephrectomy (CN) plus lung metastasectomy (LM) without targeted therapy (TT).

Jose F. Corona-Cruz

e16564

Minimally invasive image guided thermal ablation for recurrent renal cell carcinoma (RCC) after ipsilateral partial nephrectomy.

Tessa N. Hudspeth

e16557

Neutrophil-to-lymphocyte ratio as a potential prognostic factor of disease-free survival in high-risk renal cell carcinoma: Analysis of the S-TRAC trial.

Anup Patel

4562

NIVES study: A phase II trial of nivolumab (NIVO) plus stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC).

Cristina Masini

TPS4602

Nivolumab (nivo) for patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC): A single-institution experience.

Jad Chahoud

4585

Novel oral nano-amorphous sirolimus formulation to exhibit comparable exposure to intravenously administered temsirolimus: An oral alternative to the treatment of mTOR-responsive malignancies.

Hristos Glavinas

e16555

Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study.

Xiao X. Wei

TPS4600

Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) and sarcomatoid dedifferentiation (sRCC) after treatment with immune checkpoint inhibitors (ICI): A single-institution retrospective study.

Jeremy Aaron Ross

4583

Overall survival (OS) by clinical risk category for high dose interleukin-2 (HD IL-2) treated metastatic renal cell cancer (RCC): Data from PROCLAIM.

Mayer N. Fishman

4578

Patient-reported frustrations in renal cell carcinoma (RCC) care delivery: Results of a joint European Association of Urology (EAU)/KCCure survey.

Cristiane Decat Bergerot

4570

Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).

Bernard Escudier

4511

Patterns of relapse and implications for post-nephrectomy surveillance for patients with high-risk non-clear cell renal cell carcinoma: Subgroup analysis of the phase 3 ECOG-ACRIN E2805 trial.

Vivek Narayan

4564

Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC).

Nizar M. Tannir

4509

Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.

David F. McDermott

4500

Percutaneous microwave ablation under ultrasound guidance for renal cell carcinomas at clinical staging T1: A comparative study of clinical results for patients aged between less than 65 years and 65 years and older.

Zhigang Cheng

e16574

PET/CT assessment of tumor perfusion (TP) in metastatic renal cell cancer (RCC) patients (pts) on sunitinib (S) using 62Cu-ETS.

Theodore F. Logan

e16567

Phase ib and phase II studies of pembrolizumab (P) with bevacizumab (B) for the treatment of metastatic renal cell carcinoma (RCC): BTCRC-GU14-003.

Arkadiusz Z. Dudek

4558

Pilot trial of ibrutinib plus nivolumab in patients with metastatic renal cell cancer (mRCC): results from a dose-finding cohort.

Primo Lara

4580

Predictors of progressive disease (PD) and subsequent outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo).

Haris Zahoor

e16563

Prospective phase II multi-center study of individualized axitinib (Axi) titration for metastatic renal cell carcinoma (mRCC) after treatment with PD-1 / PD-L1 inhibitors.

Moshe Chaim Ornstein

4517

Prospective, multinational, observational study of real-world treatment outcomes with pazopanib in patients with advanced or metastatic renal cell carcinoma (PRINCIPAL Study).

Manuela Schmidinger

4574

PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).

Lauren Christine Harshman

TPS4597

Quality-adjusted time without symptoms or toxicity (Q-TWiST): Analysis of cabozantinib (Cabo) vs sunitinib (Sun) in patients with advanced renal cell carcinoma (aRCC) of intermediate or poor risk (Alliance A031203).

Ronald C. Chen

4556

Radiofrequency ablation of pathologically proven T1a renal tumors: 15 years follow up—A tertiary cancer center experience.

Mohamed E. Abdelsalam

4582

Real world experience and biomarkers of nivolumab in dutch advanced renal-cell carcinoma patients.

Saskia Lisa Verhaart

4572

Real world experience with nivolumab in Indian patients with metastatic renal cell carcinoma: A single centre experience.

Amit Rauthan

e16546

Replication stress response deficiency (RSRD) and response to immune therapy in clear cell renal cell carcinoma (ccRCC).

Patrick Glen Pilie

4566

Risk of health-related quality of life and metabolic events and pulmonary toxicities in patients with advanced renal cell carcinoma treated with everolimus: A meta-analysis of phase 3 randomized controlled trials.

Rachana Yendala

e16551

Risk of hematological, gastrointestinal, and hepatic toxicities in patients with advanced renal cell carcinoma treated with everolimus: A meta-analysis of phase 3 randomized controlled trials.

Henry Palangdao Igid

e16553

Safety and activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma: A cytokine working group phase II study.

Leonard Joseph Appleman

4573

Selection for active surveillance in mRCC by the CLEAR multigene score.

Ravindran Kanesvaran

e16552

Single-center analysis of 109 patients (pts) with metastatic chromophobe renal cell carcinoma (ChRCC): Differences in outcomes by histologic variant.

Yasser Ged

4577

Survival outcomes in sarcomatoid renal cell carcinoma.

Taha Al-Juhaishi

e16559

The clinical impact of serum C-reactive protein levels in metastatic renal-cell carcinoma patients treated by second-line molecular targeted therapies.

Kimiharu Takamatsu

e16572

Therapeutic benefit of empiric drug sequencing in metastatic renal cell carcinoma.

Viola Chen

e16569

Treatment patterns and effectiveness outcomes in patients with stage IV, renal cell carcinoma.

Ronda Copher

e16571

Using real-world data to develop clinical trial referral networks for metastatic renal cell carcinoma (mRCC).

Nobumasa Kawasaki

e16556

Vorolanib (CM082), everolimus, and the combination in patients with pretreated metastatic renal cell carcinoma (CONCEPT study): A randomized, phase 2/3, double-blind, multi-center trial.

Jun Guo

TPS4605